SecBot SecBot
Biotech Drug Report Generated Aug 18, 2026

SIMPONI

JNJ·JOHNSON & JOHNSON
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved (marketed); no pivotal-stage program pending for this molecule
Time to market
Already approved and marketed, subcutaneous Simponi approved in 2009 and the intravenous Simponi Aria form cleared FDA in July 2013 (per the recorded JNJ FDA-approval catalyst on 2013-07-18); no new approval pending for JNJ.
Why 3/10
Simponi is already approved and marketed with no pending JNJ regulatory decision in the next ~12 months, the closest dated event is Alvotech's expected late-2026 FDA decision on AVT05, a proposed golimumab biosimilar, which is a competitive threat to the franchise but not a JNJ catalyst, so the score stays at 3 (approved drug, minor asset inside a mega-cap portfolio).
Actionable Insight NEUTRAL

There is no binary JNJ event tied to Simponi, watch instead for the FDA decision on Alvotech's AVT05 golimumab biosimilar (expected ~late 2026 after its June 2026 BLA resubmission and six-month review), which would accelerate erosion of Simponi sales. For JNJ stock, Simponi is a legacy anti-TNF line item; the real drivers are the broader pharma pipeline, and the stock currently trades around $262 with a mean analyst price target of $272.50 (implied upside ~6.7%).

Price Chart

Loading chart...

Executive Summary

Simponi/Simponi Aria (golimumab) is Johnson & Johnson's Janssen-developed anti-TNF biologic, approved for several inflammatory conditions and recorded in SecBot's FDA-catalyst data with a July 18, 2013 approval event for the IV form. It is a mature, marketed asset inside a mega-cap whose whole thesis does not depend on it, JNJ trades near $262 with a buy-leaning analyst consensus (mean target $272.50). The most market-relevant near-term development is competitive, not company-driven: Alvotech (ALVO) resubmitted its AVT05 golimumab biosimilar BLA to the FDA in June 2026 with a decision expected late 2026, which would pressure Simponi's franchise.

How It Works

Simponi (golimumab) is an injectable biologic, a lab-made antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF), a protein that drives inflammation in autoimmune diseases. Blocking TNF dampens the joint and gut inflammation behind rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and ulcerative colitis. It comes as a self-injected shot (Simponi) and an IV infusion (Simponi Aria).

Trial Status

Golimumab is fully approved and commercialized. The only active JNJ-sponsored clinical work in the local pipeline database is a completed Phase 2 study (NCT05071664, 91 patients) of guselkumab + golimumab combination therapy in psoriatic arthritis, which finished primary completion May 2024 with results posted. The regulatory front is now on the biosimilar side: Alvotech resubmitted its AVT05 BLA (a proposed biosimilar to Simponi/Simponi Aria) to the FDA on June 4, 2026, with an expected six-month FDA review.

The Two-Sided Case

▲ Bull Case4
Simponi remains an approved, marketed revenue stream for JNJ across multiple indications (RA, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis), and JNJ's SecBot-recorded FDA-approval history shows the franchise cleared regulators as recently as the July 2013 Simponi Aria approval.
JNJ is a fortress mega-cap: current price ~$262.37 with an analyst consensus of 15 buy + 7 strong buy vs 0 sell ratings, a mean price target of $272.50 and median of $280 (22 analysts, implied upside ~6.7%), and deep institutional ownership (BlackRock alone reported ~$53.9B of JNJ in 2026-Q2 13F data).
JNJ still runs combination-development work on golimumab, a completed Phase 2 trial (NCT05071664) of guselkumab + golimumab in psoriatic arthritis with results, showing the molecule retains some pipeline utility.
Recent 13F data show broad tracked-manager accumulation in JNJ in 2026-Q2 (e.g., T. Rowe Price +39.4%, Capital World +29.5%, Norges Bank new position), and JNJ is up ~53.9% over 12 months per quant data.
▼ Bear Case4
Direct biosimilar threat is imminent: Alvotech resubmitted its AVT05 BLA, a proposed biosimilar to Simponi and Simponi Aria (golimumab), to the FDA on June 4, 2026, and the FDA's six-month review means a decision around late 2026; a U.S. golimumab biosimilar would erode Simponi pricing and share.
Simponi is a small, mature, ex-growth part of a vast JNJ portfolio with no upcoming JNJ-specific catalyst for this drug, no binary, just slow competitive decay; JNJ's broader forward P/E is ~23.7 with 30-day estimate revisions deteriorating (-4 net per quant data).
JNJ insiders have been sellers (CEO Joaquin Duato sold ~$26.7M and ~$5.5M of stock on Aug 13, 2026, plus earlier sales), and JNJ faces unrelated overhangs such as talc litigation (recorded court/enforcement rows).
The anti-TNF class is crowded (Remicade, Humira, Enbrel and their biosimilars) and JNJ's own newer immunology agents outrank golimumab in strategic priority, so Simponi is positioned for decline rather than growth.

Upcoming Catalysts

  • FDA decision on Alvotech's AVT05 golimumab biosimilar, expected ~late 2026 (six-month review of June 4, 2026 resubmission), a negative overhang for the Simponi franchise and a positive catalyst for ALVO
  • JNJ quarterly earnings/immunology sales disclosures for golimumab (next reports follow the 10-Q cadence; latest 10-Q filed 2026-07-23)
  • Any JNJ label or pediatric/indication updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

JOHNSON & JOHNSON 8-K JNJ ·Originating report

Sources · 5

Hover a chip for the title
1 sec.gov2 sec.gov3 globenewswire.com4 globenewswire.com5 globenewswire.com